Patent intelligence · US
US 11548940
Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Patent details — US 11548940
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 10, 2023
- Expiration
- Jan 5, 2043
- Applicant
- Rani Therapeutics, LLC
- Claims
- 46
- CPC classes
- A61K, A61K2039/542, A61K38/26, A61K38/28
Quick answer
US 11548940 (Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device) is held by Rani Therapeutics, LLC. Status: granted. Granted Jan 10, 2023. Expires Jan 5, 2043 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Rani Therapeutics, LLC
- Grant date
- Expiration
- Claims
- 46
- CPC classes
- A61K, A61K2039/542, A61K38/26, A61K38/28, A61K39/00114
More from Rani Therapeutics, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12357555
Self-emulsifying composition, intended for administration onto the skin, containing biosurfactant, cosurfactant and oil phase
granted -
US 12268831
Swallowable drug delivery device and methods of drug delivery
granted -
US 12263325
Device, system and methods for the oral delivery of therapeutic compounds
granted -
US 12214019
Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
granted -
US 12201721
Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
granted -
US 12168692
Antibodies targeting CCR2
granted -
US 12128133
Ingestible device with expandable enclosure
granted -
US 12077551
Zinc complex, preparation thereof and use thereof for trerapy of human and animal diseases
granted
Frequently asked questions
What is US patent 11548940?
US 11548940 (Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device) is held by Rani Therapeutics, LLC. Status: granted. Granted Jan 10, 2023. Expires Jan 5, 2043 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11548940?
Rani Therapeutics, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 148 pharmaceutical patents for this assignee.
When does US 11548940 expire?
Our index shows an expiration date of Jan 5, 2043 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.